H.C. Wainwright analyst Emily Bodnar tells investors that the clinical hold on Arcellx’s iMMagine-1 trial due to a patient’s death is a “minor setback” for the company as the patient should not have received treatment and does not change the fundamental story. The firm, which made no change to its Buy rating or $49 price target, expects the company and the FDA to come to a resolution in about three months.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACLX:
- Arcellx price target lowered to $57 from $60 at Truist
- Arcellx Plummets on Clinical Hold on Phase 2 Multiple Myeloma Trial
- Arcellx price target lowered to $40 from $55 at Baird
- Arcellx announces clinical hold for iMMagine-1 Phase 2 clinical program
- Fly Insider: Lyra, Arcellx among week’s notable insider trades